DMAA seeks consensus on DM outcome measures

Innovative contracts are becoming more common for gene therapies. They aim to balance a therapy’s cost-effectiveness and affordability, as well as address the uncertainty of long-term benefit.

Psychiatrists and psychologists also had lower in-network reimbursement rates.

In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.

Panelists discussed reaching beyond large patient advocacy groups for input and how clinical trial endpoints may paint an incomplete picture of a drug's true value to patients.

Ross Margulies, J.D., M.P.H., a partner at the Foley Hoag law firm, discusses proposals to “delink” what pharmacy benefit managers are paid from the price of drugs.